| 6.4.1 Female sex hormones |
Primary Care Management of Menopause Click here |
| |
6.4.1.1 Oestrogens and HRT
|
Guidance is given below on the type of product required in different situations. The choice of actual preparation (tablet,
|
patch, gel) to remain with the prescriber bearing in mind patient preference and the cost differences between the preparations.
|
| |
Note: HRT should only be used for osteoporosis prevention in patients where other therapies are contra-indicated, not tolerated,
|
| or there is a lack of response. This should ideally be under the direction of a specialist. |
| |
Women with uterus
|
Sequential preparations for patients with an intact uterus & perimenopausal i.e. have not yet had 1 year amenorrhoea.
|
| |
GREEN 1st line Elleste Duet 1mg, 2mg (Estradiol / norethisterone combination)
|
GREEN 2nd line Femoston 1/10, 2/10 (Estradiol / dydrogesterone combination)
|
| |
Continuous combined preparations for period free HRT, should only to be used in patients who are amenorrhoeic for 1 year
|
or over 54 years if currently on sequential preparation.
|
| |
GREEN 1st line Elleste-Duet Conti (Estradiol/ norethisterone continuous 'no bleed' combination)
|
GREEN 2nd line Femoston-Conti (Estradiol/ dydrogesterone continuous 'no bleed' combination)
|
GREEN 3rd line Premique (Conj. oestrogens/ medroxyprogesterone continuous 'no bleed' combination)
|
BLACK 0.45mg conjugated oestrogens & Bazedoxifene (Duavive®)
|
| GREEN Oestrogel 17β-estradiol Pump Pack 0.06% gel |
| |
| Bijuve® [GREEN Restricted] |
| > Bijuve® is an alternative when other HRT treatments have not been tolerated or when Femoston-Conti® is being considered OR |
| > Bijuve replaces HRT regimens where separate oestrogen and micronised progesterone are used (single hormone products |
used in combination are more expensive than Bijuve®)
|
| GREEN Estradiol/ micronised progesterone ( Bijuve®) |
| Restricted |
| |
|
Progestogenic opposition of oestrogen HRT in women with an intact uterus
|
| GREEN Micronised Progesterone 100mcg capsules [Utrogestan®] |
| |
HRT should be trialled for 4 months and reviewed. If progesterone side effects are reported consider switching to Femoston
|
products. If oestrogen side effects are reported switch to Prempak-C/ Premique. If side effects of both are severe, consider
|
transdermal patches (Evorel Sequi or Evorel Conti).
|
HRT patches should be reserved for use in patients with diabetes, liver disease or severe side effects.
|
| |
GREEN Evorel Sequi 50,and 50/170 micrograms in 24 hours (Estradiol/ norethisterone sequential combination)
|
GREEN Evorel Conti 50/170 micrograms in 24 hours (Estradiol/ norethisterone continuous 'no bleed' combination)
|
| |
Women without uterus
|
Unopposed oestrogen is used for patients with hysterectomy, however in endometriosis, endometrial foci may remain and the use of combination preparations should be considered.
|
| |
GREEN 1st line Elleste Solo 1mg, 2mg (Estradiol)
|
GREEN 2nd line Premarin 0.625, 1.25 (Conjugated oestrogens)
|
HRT patches should be reserved for use in patients with diabetes, liver disease or severe side effects.
|
GREEN Evorel 25, 50, 75, 100 (micrograms in 24 hours) (Estradiol)
|
| |
Where patches are not tolerated but symptoms of menopause require treatment, estradiol gel is an option.
|
GREEN Estradiol gel (Sandrena), 500mcg/sachet & 1mg/sachet
|
GREEN 17β-estradiol Pump Pack 0.06% gel [Oestrogel® pump pack]
|
|
| Back to main page |
| |
| Testosterone [transdermal] |
| Off-label indication: As Supplementation for Postmenopausal women with low sexual desire if HRT alone is not effective. |
| The use of these products is unlicensed for this indication. Tostran 2% gel should be considered before other preparations as |
| the dose is measurable. |
| > The diagnosis of HSDD must involve a full clinical assessment and other factors contributing to female sexual arousal disorder |
| (FSD) must be identified and addressed before testosterone therapy is initiated. |
| > Women must be counselled on the absence of long-term safety data for the use of testosterone in women |
| > Women must be counselled on the unlicensed nature of the testosterone products available and the implications of this. |
| > Tostran should be considered before other preparations as the dose is measurable. We recommend a dose not exceeding |
one full depression of the canister piston (10 mg testosterone) on alternate days.
|
| > Patients should be monitored for their clinical response to treatment and assessed for signs of androgen excess with a serum |
| total testosterone level every 6 months, to screen for overuse. If no benefit is experienced by 6 months, treatment should be |
| ceased. |
| > In the absence of long-term safety data, women with a history of breast cancer or with a known high risk of breast cancer |
should not be prescribed testosterone.
|
| > In the absence of long-term safety data, women with cardiovascular disease and/or uncontrolled hypertension should not be |
| prescribed testosterone. |
| > In patients receiving long-term androgen therapy, the following laboratory parameters should also be monitored regularly: |
| haemoglobin, and haematocrit (to detect polycythaemia), liver function tests, and lipid profile. |
| > Improved insulin sensitivity may be observed in patients treated with androgens and may require a decrease in the dose of |
| antidiabetic medications. |
| Further patient information is available via the RCOG menopause hub: |
| https://www.rcog.org.uk/for-the-public/menopause-and-later-life/ |
| Link to New Medicine Recommendation |
| Please see the Shared Care Guideline here |
| AMBER shared care Testosterone transdermal gel |
Tostran® 2% gel [to be considered first], Testim® 50mg/5g gel in tube, Testogel® 50mg/5g gel in sachet
|
| |
Tibolone
|
Tibolone increases the risk of breast cancer recurrence in women with a history of breast cancer. Tibolone should not be used
|
in women with known or suspected breast cancer, or in those with a history of breast cancer. It should be used for loss of libido only.
|
| |
GREEN Tibolone tablets 2.5mg
|
| |
6.4.1.2 Progestogens and progesterone receptor modulators
|
GREEN Medroxyprogesterone tablets 5mg,10mg
|
GREEN Norethisterone tablets 5mg
|
GREEN Progesterone pessaries 200mg, 400mg
|
| GREEN Progesterone caps 100mg [Utrogestan®, natural micronised progesterone] |
| |
| Clonidine 25mcg tablets - for vasomotor symptoms associated with menopause |
| Where HRT is contraindicated or declined, a trial of clonidine 25mcg tablets may be considered for menopausal VMS. |
| Patients should be reviewed after 4 weeks and if no improvement in symptoms is observed or the patient is experiencing |
| significant adverse events, treatment should be discontinued. |
| GREEN [restricted use] Clonidine 25mcg tablets |
| |
| |
| Moderate to severe symptoms of uterine fibroids |
| Relugolix-estradiol-norithisterone acetate - for treating moderate to severe symptoms of uterine fibroids in adults of |
| reproductive age is recommended, within its marketing authorisation as an option in NICE TA832 |
| AMBER relugolix-estradiol–norethisterone acetate [Ryeqo] |
| |
| |
MHRA 18th March 2020 - UPDATE
|
| |
| ESMYA [Ulipristal acetate]- License suspended to protect public health while a safety review is conducted following a further |
| case of liver injury requiring transplant
|
| [Indications: > Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age |
| > Pre-surgical treatment of moderate to sever symptoms of uterine fibroids in adult women of reproductive age] |
